
Opinion|Videos|March 10, 2025
A Primary Care Perspective on Newer-Generation Systemic Therapies
Panelists discuss how primary care awareness of biologics and Janus kinase (JAK) inhibitors for atopic dermatitis (AD) remain limited, with outreach efforts by dermatology groups and industry partners showing mixed success in education. While patients on biologics generally report significant symptom improvement, measured through validated tools like EASI, SCORAD, and patient-reported outcome measures, ongoing efforts are needed to bridge the knowledge gap in primary care settings.
Advertisement
Episodes in this series

Video content above in prompted by the following:
- How would you characterize awareness of systemic treatments like biologics and JAK inhibitors for the treatment of AD among primary care practitioners?
- Are the dermatology community/industry/primary care partners /educational meetings reaching primary care providers?
- Do patients using biologics typically report satisfactory improvement in symptoms?
- How do you quantify/assess such improvements?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Prevalence and Recognition of Hypercortisolism
3
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
4
METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
5


























































































